S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Zacks Investment Research Lowers Aspira Women's Health (NASDAQ:AWH) to Sell

Last updated on Friday, January 14, 2022 | 2022 MarketBeat

Aspira Women's Health (NASDAQ:AWH) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a report issued on Friday, Zacks.com reports.

According to Zacks, "Aspira Women's Health Inc. engaged in the discovery, development and commercialization of testing options and bio-analytical solutions for women's health. Aspira Women's Health Inc., formerly known as Vermillion Inc., is based in AUSTIN, Texas. "

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Aspira Women's Health in a report on Tuesday.

NASDAQ:AWH traded down $0.01 on Friday, hitting $1.30. The stock had a trading volume of 25,674 shares, compared to its average volume of 748,198. The company has a debt-to-equity ratio of 0.07, a quick ratio of 7.34 and a current ratio of 7.36. The stock has a market cap of $145.77 million, a P/E ratio of -1.67 and a beta of 2.88. Aspira Women's Health has a 1 year low of $1.30 and a 1 year high of $10.54. The firm's fifty day simple moving average is $2.00 and its two-hundred day simple moving average is $3.26.

Aspira Women's Health (NASDAQ:AWH) last issued its quarterly earnings results on Wednesday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by ($0.02). Aspira Women's Health had a negative return on equity of 78.11% and a negative net margin of 449.23%. The company had revenue of $1.67 million for the quarter, compared to analysts' expectations of $1.50 million. During the same quarter in the previous year, the business earned ($0.04) EPS. Equities research analysts predict that Aspira Women's Health will post -0.27 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Arizona State Retirement System bought a new position in Aspira Women's Health in the 2nd quarter valued at $77,000. Swiss National Bank bought a new position in Aspira Women's Health in the 2nd quarter valued at $623,000. B. Riley Wealth Management Inc. boosted its holdings in Aspira Women's Health by 18.6% in the 2nd quarter. B. Riley Wealth Management Inc. now owns 470,762 shares of the company's stock valued at $2,646,000 after purchasing an additional 73,806 shares during the period. Ergoteles LLC bought a new position in Aspira Women's Health in the 2nd quarter valued at $404,000. Finally, Shell Asset Management Co. bought a new position in Aspira Women's Health in the 2nd quarter valued at $140,000. 31.52% of the stock is owned by institutional investors.

About Aspira Women's Health

Aspira Women's Health, Inc engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

See Also: What is a closed-end mutual fund (CEF)?

Get a free copy of the Zacks research report on Aspira Women's Health (AWH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Aspira Women's Health right now?

Before you consider Aspira Women's Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aspira Women's Health wasn't on the list.

While Aspira Women's Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here



Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.